Biomerica Inc (BMRA)vsEli Lilly and Company (LLY)
BMRA
Biomerica Inc
$1.62
+5.88%
HEALTHCARE · Cap: $4.94M
LLY
Eli Lilly and Company
$1,169.33
+4.86%
HEALTHCARE · Cap: $1.02T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1669625% more annual revenue ($72.25B vs $4.33M). LLY leads profitability with a 35.0% profit margin vs -96.5%. LLY earns a higher WallStSmart Score of 76/100 (B+).
BMRA
Avoid26
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -125.8% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 33.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRA
The strongest argument for BMRA centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : BMRA
The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
BMRA profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.51 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 26/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomerica Inc
HEALTHCARE · MEDICAL DEVICES · USA
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology firm focused on developing and manufacturing cutting-edge diagnostic solutions catering to both medical and food industries. The company specializes in proprietary testing methods aimed at metabolic diseases, gastrointestinal disorders, and food intolerances, positioning itself to significantly enhance healthcare outcomes and diagnostic precision. With a commitment to addressing unmet medical needs, Biomerica capitalizes on strategic research partnerships and advanced technology integration, facilitating growth in the dynamic diagnostics market. Its patient-centric strategy further underscores the potential for transformative improvements in global healthcare diagnostics, making it a compelling prospect for institutional investors.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?